Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on DPP IV Inhibitors. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel zinc-promoted asymmetric allylation for DPPIV inhibitors. High stereoselectivity, scalable route for API intermediates.
Patent CN112028806B reveals a novel synthetic method for Vildagliptin intermediates, achieving 99.7% purity and 80.6% yield through stabilized cyanuric chloride dehydration.
Patent CN103373953A reveals a safe, high-yield route for 3-aminopiperidine, offering cost-effective API intermediate manufacturing solutions.